The waveLINE-003 trial demonstrates the efficacy of zilovertamab vedotin combined with standard therapy, with manageable safety profiles in difficult-to-treat DLBCL patients. ADCs provide logistical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback